Dactinomycin
View Brand InformationWhat is Dactinomycin?
Approved To Treat
Top Global Experts
Related Clinical Trials
Summary: The purpose of this study is to evaluate the efficacy and safety of camrelizumab and apatinib as combination therapy in patients with ultra high-risk (Cohort A) and high-risk chemo-refractory or relapsed (Cohort B) gestational trophoblastic neoplasia (GTN). Eligible patients will receive camrelizumab plus apatinib plus chemotherapy. Treatment will be continued until disease progression, unacceptab...
Summary: The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment that can delay the time before your disease gets worse (progresses).
Summary: This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics as related to adaptation and extinction to populations of cancer cells that similarly adapt and that we are attempting to...
Related Latest Advances
Brand Information
- Secondary Malignancy and Leukemia
- Veno-occlusive Disease
- Extravasation
- Myelosuppression
- Immunizations
- Severe Mucocutaneous Reactions
- Renal Toxicity
- Hepatotoxicity
- Potentiation of Radiation Toxicity and Radiation Recall


